Latest Developments in USFDA Inspections India plays a crucial role in the global pharmaceutical supply chain, supplying a large share of generic medicines to markets around the world. As Indian...
Key Highlights: Implications: The merger gives HAB Pharma a bigger scale story: a cleaner corporate structure, more manufacturing capacity, and a stronger platform to sell specialty products in more ...
Key Highlights: Implications: Obeda gives Dr. Reddy’s a second GLP‑1 foothold in India, but this time in the much bigger day‑to‑day diabetes market, not just injectable semaglutide. Because it ...
Key Highlights Implications: Indoco is effectively cashing out of a non-core, lower-scale ophthalmic franchise (₹110 crore slump sale) to refocus capital and management on highe...
Latest Developments in Global Pharma Supply Chains The COVID-19 pandemic exposed critical vulnerabilities in global pharmaceutical supply chains, highlighting the risks associated with overrelia...
Key Highlights: Implications: CORONA Remedies is using the Wokadine acquisition to buy its way into India’s ₹648 crore povidone-iodine market with a #2-ranked, 46‑year-old antise...
Key Highlights: Implications: Usema adds another early DCGI‑approved semaglutide brand to India’s GLP‑1 wave, giving USV a bioequivalent, locally manufactured injectable that fits neatly i...
Key Highlights: Implications: The expanded BAT2506 deal gives Intas a late‑stage TNF‑α biosimilar in a broad immunology class, reinforcing its biologics presence in rheumatology ...
Key Highlights: Implications: Obeda’s Day‑1 launch with DCGI approval and head‑to‑head Phase III data positions Dr. Reddy’s as a clinically credible, early GLP‑1 player, even at a higher ~...
Key Highlights: Implications: By pairing one of the lowest weekly price points in the GLP‑1 segment (₹325–₹440) with a vial‑plus‑pen strategy, Glenmark is clearly targeting early initiatio...
